Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis
Related To This Subject
Share
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
Accept